Rein Therapeutics (RNTX)

• Market cap: $39.2M
• 1 day: 2.76%
• 5 days: 10.37%
• 1 month: -3.25%
• 3 months: 25.21%
• 6 months: -23.2%
• Year to date: -33.78%
• 1 year: -30.37%
• 5 years: -92.47%
• 10 years: -99.31%
• Sector: Healthcare
• Industry: Biotechnology

About: Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Employees: 11